| Outcome Measures: |
Primary: Hemoglobin A1C, Change from baseline in hemoglobin A1C after 12 weeks of colesevelam or colesevelam plus sitagliptin treatments, Baseline and 12 weeks|Fasting Plasma Glucose, Change from baseline in fasting plasma glucose concentrations after 12 weeks of colesevelam or colesevelam plus sitagliptin treatments., Baseline and 12 weeks|Fasting Endogenous Glucose Production, Change from baseline in fasting endogenous glucose production after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment, baseline and 12 weeks|Fasting Gluconeogenesis, Change from baseline in fasting gluconeogenesis after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment, baseline and 12 weeks|Fasting Glycogenolysis, Change from baseline in fasting glycogenolysis after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment, baseline and 12 weeks|Fasting Plasma Glucose Clearance, Change from baseline in fasting plasma glucose clearance after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments., baseline and 12 weeks|Appearance Rate of Oral Glucose, Change from baseline in appearance rate of oral glucose after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments, baseline and 12 weeks|Postprandial Endogenous Glucose Production, Change from baseline in postprandial endogenous glucose production after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments Mean value was calculated using all results measured between 10 and 300 min post meal., baseline and 12 weeks|Postprandial Rate of Total Glucose Disposal Area Under the Curve (AUC), Change from baseline in postprandial rate of total glucose disposal (AUC) after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments AUC was calculated by the trapezoid method using all results measured between 0 and 300 min during the meal tolerance test., baseline and 12 weeks|Whole-body Glycolytic Disposal of Oral Glucose, Change in baseline in whole-body glycolytic disposal of oral glucose after 12 weeks of colesevelam alone or colesevelam plus glucose treatments, baseline and 12 weeks|Postprandial Glucose (AUC), Comparison between baseline and 12 weeks values of postrandial glucose (AUC)., Baseline and 12 weeks | Secondary: Fasting Plasma C-peptide, To evaluate the effect of treatments on plamsa C-peptide concentrations., Baseline and 12 weeks|Fasting Plamsa Glucagon, To evaluate the effect of treatments on plasma glucagon concentrations., Baseline and 12 weeks|Fasting Active Plasma Glucagon Like-Peptide 1 (GLP-1), To evaluate the effect of treatments on plasma GLP-1 concentrations., Baseline and 12 weeks|Fasting Plasma Total Glucose-dependent Insulinotropic Peptide (GIP), To evaluate the effect of treatments on plasma Glucose-dependent Insulinotropic Peptide (GIP) concentrations., Baseline and 12 weeks|Fasting Insulin, To evaluate the effect of treatments on fasting insulin concentrations, Baseline and 12 weeks|Postprandial Insulin (AUC), To evaluate the effect of treatments on postprandial insulin (AUC), Baseline and 12 weeks|Postprandial C-peptide (AUC), To evaluate the effect of treatments on postprandial C-peptide (AUC), Baseline and 12 weeks|Postprandial Active GLP-1 (AUC), To evaluate the effects of treatments on postprandial active GLP-1 (AUC), Baseline and 12 weeks|Postprandial Total GIP (AUC), To evaluate the effects of treatment on postprandial total GIP (AUC), Baseline and 12 weeks|Postprandial Glucagon (AUC), To evaluate the effects of treatment on postprandial glucagon (AUC), Baseline and 12 weeks
|
| Locations: |
University of California, San Francisco, San Francisco, California, 94110, United States|Clinical Pharmacology of Miami, Miami, Florida, 33014, United States|Healthcare Discoveries, LLC d/b/a ICON Development Solutions, San Antonio, Texas, 78209, United States
|
